New scientific studies on Sucrosomial® Technology applied to iron

In the last few months, more and more scientific studies have been focusing on the use of Sucrosomial^® Technology applied to minerals. Specifically, 2021 was a particularly productive year for preclinical and clinical research on Sucrosomial^® Iron, with the publication of eight full articles of international relevance covering different areas of research.

Some of the most relevant and recent studies are indicated below together with a brief summary of the most significant data. The complete list of scientific studies on Sucrosomial^® Iron published in the last 12 months can be found at the end of this article. These studies can be referred to in the professional area of the Sideral.it website.

The benefits of Sucrosomial^® Iron: scientific evidence in basic research and cardiac surgery

Sucrosomial^® Iron is useful in all those areas where iron deficiency often occurs, and the publications from this year show that this problem is found in various clinical contexts. Recent publications cover gastroenterology, nephrology, cardiology and even cardiac surgery.

Indeed, a recent study on 1000 subjects was conducted by Dr. Luca Weltert, of the International University for Health Sciences ‘San Camillus’ in Rome. Research has shown Cardio SiderAL^® to be useful in preparing for elective cardiac surgery by increasing preoperative haemoglobin levels and reducing the need for blood transfusions immediately after surgery.

There is also plenty of basic research on Sucrosomial^® Iron currently underway, allowing certain qualities to be studied in in-vitro and on animal models in order to better understand the mechanism of action of SiderAL^®. One of the most interesting and innovative of these is the research carried out in collaboration with Dr. Frazer of the QIMR Berghofer Medical Research Institute in Herston, Australia. The study assesses the effects of Sucrosomial^® Iron on the intestinal microbiome, i.e. how the type and quantity of microorganisms that make up the intestinal flora changes following the intake of iron.

The study of the microbiome is a subject that has attracted increasing interest from the scientific community in recent years since it makes it possible to predict and correlate the benefits of certain substances or lifestyles with the general health of individuals through the study of the bacteria that colonise our intestines. The results of the study, carried out on iron deficient mice, showed for the first time that Sucrosomial^® Iron is able to induce positive changes in the intestinal microbiota, in contrast to conventional irons, which negatively affect the quantity and quality of the microbiota. This discovery suggests a possible explanation for the better gastrointestinal tolerability of Sucrosomial^® Iron compared to conventional oral irons, which are known to be poorly tolerated and cause typical adverse effects such as gastralgia, diarrhoea or constipation.

The impact of Sucrosomial^® Technology in different clinical settings

The scientific studies mentioned show how Sucrosomial^® Technology, with its unique and patented mechanism of action, can make a difference in very different clinical settings, but which all have issues related to iron absorption and blood resource management.

For years PharmaNutra research, thanks to the collaboration with the main Italian Universities and numerous foreign research institutes, has been carrying out clinical and basic studies that include the widest possible number of medical fields, with the aim of demonstrating how the use of Sucrosomial^® Iron represents a valid alternative to the common iron-based formulations currently on the market. Concrete benefits, which have a positive impact on every clinical aspect: from reduced gastrointestinal tolerability issues to increased patient compliance, reduced need for transfusions and reduced need for intravenous iron supplementation, resulting in lower healthcare costs.

Below are the bibliographic references of the most recent scientific studies on Sucrosomial^® Technology applied to iron. The articles are available to healthcare professionals and can be found in full at areariservata.sideral.it:

• Karavidas A et al. Oral Sucrosomial iron improves exercise capacity and quality of life in heart failure with reduced ejection fraction and iron deficiency: A nonrandomized, open-label, proof-of-concept study. Eur J Heart Fail 2021 Jan 9
• Bertani L et al. Oral Sucrosomial Iron Is as Effective as Intravenous Ferric Carboxy‐Maltose in Treating Anemia in Patients with Ulcerative Colitis. Nutrients 2021, 13, 608.
• Bastida G et al. Sucrosomial Iron Supplementation for the Treatment of Iron Deficiency Anemia in Inflammatory Bowel Disease Patients Refractory to Oral Iron Treatment. Nutrients 2021, 13, 1770.
• Asperti M et al. Iron distribution in different tissues of homozygous Mask (msk/msk) mice and the effects of oral iron treatments. Am J Hematol. 2021;1–11.
• Reggiani F et al. Preliminary experience on the use of sucrosomial iron in hemodialysis: focus on safety, hemoglobin maintenance and oxidative stress. Int Urol Nephrol. 2021 Sep 12.
• Mazgaj R et al. Comparative Evaluation of Sucrosomial Iron and Iron Oxide Nanoparticles as Oral Supplements in Iron Deficiency Anemia in Piglets. Int J Mol Sci. 2021 Sep 14;22(18):9930.
• Zakrzewski M et al. Supplementation with Sucrosomial iron leads to favourable changes in the intestinal microbiome when compared to ferrous sulfate in mice. 2021 Oct 25.
• Pierelli et al. Preoperative Sucrosomial Iron Supplementation Increases Haemoglobin and Reduces Transfusion Requirements in Elective Heart Surgery Patients: A Prospective Randomized Study. Surg Technol Int. 2021 Oct 28;39: sti39/1512